Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation

This publication has 10 references indexed in Scilit:

• Virokines: novel immunomodulatory agents
  Expert Opinion on Biological Therapy, 2001
• VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN IS CAPABLE OF PROTECTING XENOENDOTHELIAL CELLS FROM ANTIBODY BINDING AND KILLING BY HUMAN COMPLEMENT AND CYTOTOXIC CELLS1
  Transplantation, 2001
• RETRACTED: Crystal Structure of a Complement Control Protein that Regulates Both Pathways of Complement Activation and Binds Heparan Sulfate Proteoglycans
  Cell, 2001
• Conserved Surface-Exposed K/R-X-K/R Motifs and Net Positive Charge on Poxvirus Complement Control Proteins Serve as Putative Heparin Binding Sites and Contribute to Inhibition of Molecular Interactions with Human Endothelial Cells: a Novel Mechanism for Evasion of Host Defense
  Journal of Virology, 2000
• EFFECT OF REPETITIVE HIGH-DOSE TREATMENT WITH SOLUBLE COMPLEMENT RECEPTOR TYPE 1 AND COBRA VENOM FACTOR ON DISCORDANT XENOGRAFT SURVIVAL1,2
  Transplantation, 1996
• Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein
  The Journal of Infectious Diseases, 1992
• A TECHNIQUE OF CERVICAL HETEROTOPIC HEART TRANSPLANTATION IN MICE
  Transplantation, 1991
• Inhibition of the Complement Cascade by the Major Secretory Protein of Vaccinia Virus
  Science, 1990
• THE MECHANISM OF DISCORDANT XENOGRAFT REJECTION
  Transplantation, 1988
• Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins
  Nature, 1988